Economic information and modeling report
Modeling overview
60 evidence topics · 33 sources
Summary: published cost-effectiveness analyses of AMT-130 and of disease-modifying therapy in Huntington's disease
- A cost-effectiveness analysis of tominersen and AMT-130 in Huntington's disease (HD) used a Markov model with four health states (early, middle, late, and death) from a modified societal perspective, with a 1-year cycle length, a 3% annual discount rate, and 30 annual cycles. All patients entered in the early stage, and utilities for both treatments were assumed equal to standard of care because trial-based utility data are not yet available. Lacking established cost data, the authors assumed the cost of AMT-130 to be the list price of Zolgensma, applied a 15% payer discount to estimate a one-time dose at $1,806,250, and used an AMT-130 administration cost of $23,516. Compared with standard of care, AMT-130 increased costs by $1.49 million and QALYs by 5.23, for an incremental cost-effectiveness ratio of $285,703 per QALY gained; the ratio for tominersen was $2.28 million per QALY gained. The authors applied a willingness-to-pay threshold of $500,000/QALY gained because HD is a rare disease. AMT-130 had an 80% probability of being cost-effective at $350,000/QALY gained, 30% at $250,000 per QALY gained, and 0% for both treatments at $100,000–150,000 per QALY gained. Adding the value of hope changed the AMT-130 ratio to $236,540 per QALY gained. The ratios were most sensitive to drug costs and to early and middle-stage utilities, and the authors state that the model relied heavily on the assumption of sustained benefit beyond the data.
- A U.S. decision-modeling framework for future disease-modifying treatments estimated lifetime costs of HD of $508,200 for the PFD population, $1.15 million for SF1 individuals, and $1.07 million for SF2 individuals; the authors did not assign a price to a disease-modifying treatment because the treatments under development vary in mechanism, route of administration, and once versus recurrent therapy.
- A United Kingdom model fitted a continuous-time hidden Markov disease progression model with five states to Enroll-HD data, and its cost modelling showed that indirect costs such as state benefits and lost gross domestic product contribution could drive the societal cost of HD over health and social care costs.
- In a PTC Therapeutics-funded analysis of eladocagene exuparvovec-tneq, the administration cost, a proxy for the cost of the stereotactic procedure, was $106,030 and the incremental cost per QALY ranged from $199,007–$224,104.
Summary: ICER assessment of AMT-130 and its model analysis plan
- Scope and timeline: the Institute for Clinical and Economic Review (ICER) is assessing the comparative clinical effectiveness and value of AMT-130 for Huntington's disease, with public discussion at a Midwest CEPAC meeting in March 2027. The population of focus is adults with early symptomatic Huntington's disease, the comparator is usual symptomatic care, and the draft scope set publication of the model analysis plan for November 16, 2026. The revised scope proposes assessing AMT-130 under an adaptation of the ICER Value Framework for single and short-term therapies, with analyses from the health care system perspective and the modified societal perspective and outcomes of years of independent living gained, life-years gained, QALYs gained, and evLYs. The revised scope states that uniQure had been unwilling to speak with ICER and, at uniQure's request, that uniQure did not participate in the process and did not review or approve the methodology, findings, or conclusions.
- Framework: under ICER's single and short-term therapy adaptations, analyses include a 50/50 shared savings model, in which 50% of lifetime health system cost offsets are assigned to the health system, and a cost-offset cap model, in which cost offsets are capped at $150,000 per year, the top of the ICER range for value-based pricing for an additional QALY. A threshold analysis for the durability of effect estimates the duration of benefit AMT-130 would need to reach standard cost-effectiveness thresholds.
- Structure: the model analysis plan describes a cohort Markov model comparing AMT-130 added onto usual symptomatic care with usual symptomatic care alone over a lifetime horizon, from a health care sector perspective in the base case, with a one-year cycle and costs and outcomes discounted at 3% per year. Health states follow Shoulson and Fahn staging by Total Functional Capacity (TFC): stage 1 (TFC 11-13), stage 2 (TFC 7-10), stage 3 (TFC 3-6), stage 4 (TFC 1-2), and stage 5 (TFC 0). All patients enter in stage 1, based on a baseline TFC of 12.1 in the pivotal trial's primary analysis, and the target population is adults with early manifest HD, with inputs from the high-dose arm.
- Natural history and treatment effect: on usual symptomatic care, TFC declines at a constant rate of -0.23 TFC/year, from a linear regression of Enroll-HD cohort B TFC scores at baseline, 12, 24, 36 and 48 months. On AMT-130, progression follows the observed TFC trajectory up to 48 months; afterwards, the base case applies the usual care decline rate reduced by 61%, the treatment effect on TFC at 48 months, or rates estimated by the clinical team, and durability remains over the lifetime. A scenario applies a 44% slowing of TFC progression based on cUHDRS, and other scenarios address natural history, durability, waning, outcome-based payment arrangements, and a premanifest population.
- Other inputs: mortality follows U.S. general population life tables with stage-specific excess mortality (0.000 in SF stage 1 to 0.146 in SF stage 5); utilities range from 0.78 in SF stage 1 to 0.22 in SF stages 4 and 5; costs are in 2025 US dollars. Peri-operative and treatment-related serious adverse events are applied as one-time costs at rates of 16.4% ($10,645) and 19.2% ($19,501). All-cause background costs from Medicaid claims are $28,454 in early, $69,016 in middle, and $118,889 in late HD, and indirect costs are $85,656, $133,500, and $112,816.
- Price, outcomes, and budget impact: the placeholder price is $2,600,000, the midpoint of analyst estimates from $1,700,000 to $3,500,000, and the administration price of $24,138.83 is based on the estimates of an earlier AMT-130 model. Outcomes include years of independent life and years free of full-time care; probabilistic sensitivity analysis uses 1,000 simulations, and threshold analyses for drug costs span $50,000, $100,000, $150,000, and $200,000 per QALY and evLY gained. Budget impact is estimated over a five-year time horizon for 25,811 eligible patients, of whom 20% initiate treatment each year (5,162 patients per year), against a threshold of approximately $709 million per year.
Summary: price basis, other gene therapy prices, and payment models
- In June, Leerink analysts estimated a U.S. price of $1.7 million and worldwide sales of $2.5 billion in 2030 if AMT-130 is approved. The ICER placeholder price of $2,600,000 rests on estimates from $1,700,000 by Leerink Partners to $2,500,000 - $3,500,000 by IPD analytics. uniQure's annual report states that third-party payers and ICER increasingly challenge prices and examine budget impact and cost-effectiveness, and that the CMS GENEROUS Model requires rebates aligned with Most Favored Nation pricing to participating state Medicaid programs.
- Prices of other products: Zolgensma, a one-time treatment, $2.125 million list price ($425,000 per year for five years); the gene therapy Hemgenix, $3.5 million list price, for which ICER had used a $4 million placeholder price and found a Health Benefit Price Benchmark of $2.93 million to $2.96 million; Roctavian, $2.9 million wholesale acquisition cost; the gene therapy Elevidys, $3.2 million wholesale acquisition cost; the gene therapy Beqvez, $3.5 million; eladocagene exuparvovec-tneq, $3,950,000 U.S. wholesale acquisition cost. BioMarin announced that it will voluntarily remove Roctavian from the market, and Pfizer is ending global development and commercialization of Beqvez.
- Payment models: Novartis' AveXis worked with payers on five-year outcomes-based pacts and pay-over-time options for Zolgensma. BioMarin offered an outcomes-based warranty for Roctavian reimbursing up to 100% of wholesale acquisition cost on a prorated basis if response is lost in the first four years, and will honor existing outcomes-based agreements after withdrawal. Pfizer launched a warranty program for Beqvez based on durability of response, and CSL Behring offered a substantial rebate for Hemgenix if patients return to prophylactic factor IX during the first 3 1/2 years. One publication on gene therapy payment groups value-based contracts into milestone-based rebates, warranties, and performance-based installment payments, and names patients changing insurers and Medicaid Best Price provisions, which apply to all value-based contracts except warranties, as barriers.
- CMS Cell and Gene Therapy Access Model: a multi-year, voluntary model for states and manufacturers that tests a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies in Medicaid, initially focused on gene therapy for sickle cell disease, with 34 state participants and 2 manufacturer participants; states began participation between January 2025 and January 2026.
Summary: eligible population inputs and budget impact evidence
- The report holds no budget impact model for AMT-130; every leaf of its Budget Impact Model section reads No evidence found.
- ICER eligible population: approximately 40,000 people with Huntington's disease in the U.S. in 2020 (a prevalence rate of approximately 0.012%), approximately 62.7% of whom are in SF stage 1 or 2, applied to approximately 342 million people averaged over 2026-2030, gives 25,811 eligible patients, with 20% initiating treatment in each of the five years (5,162 patients per year). The exploratory preclinical population is 100,000 people (approximately 200,000 at risk multiplied by the 50% likelihood of inheriting the mutation), with 20,000 initiating treatment per year.
- Prevalence and stage distribution: in a study population of 38.4 million individuals who met a continuous enrollment requirement, the prevalence rate was 6.7 per 100,000 in 2020 and 9.4 per 100,000 in 2024. In British Columbia, prevalence was 13.7 per 100,000 in the general population. In an insurance database of over 67 million enrollees, 1.18% of those diagnosed were 20 years old or less. In one study, most participants were in TFC stages I–III, with 41.3% in stage II (n = 845 in stage I, n = 1068 in stage II, n = 540 in stage III, n = 116 in stage IV, and n = 15 in stage V).
- Other population inputs: pooled incidence was 0.48 cases per 100,000 person-years; median survival time in one cohort was 12.4 years; and in one study, 49.9% of people with Huntington's disease received neurologist care in a calendar year.
- Budget impact method: ICER will use the placeholder price of $2,600,000 and threshold prices at $50,000 to $200,000 per evLY gained, with undiscounted costs over five years, against a potential budget impact threshold of approximately $709 million per year for 2026-2027. uniQure lists increased diagnosis due to genetic testing and disease-modifying treatment availability, and an increase in addressable patient segments, as potential long-term growth levers.
- Reference analysis: in a CSL Behring-funded budget impact analysis of etranacogene dezaparvovec priced at $3,500,000 in a hypothetical 1-million-member plan over 5 years, 1.8 people were eligible and the cumulative budget impact was $848,509, with incremental annual costs of $79,824 to $271,435 and per-member per-month costs of $0.007 to $0.023; results were sensitive only to the uptake assumptions.
Health technology assessment: ICER assessment page and public meeting
Health technology assessment: ICER revised scope, single and short-term therapy framework
Health technology assessment: ICER revised scope, perspective and Shoulson and Fahn health states
Health technology assessment: manufacturer participation in the ICER review
Health technology assessment: ICER research protocol, research question and review components
ICER model analysis plan: aim, comparator, perspective, and framework adaptations
ICER model analysis plan: model structure and health states
ICER model analysis plan: key model assumptions
ICER model analysis plan: target population and baseline characteristics
ICER model analysis plan: natural history input from Enroll-HD
ICER model analysis plan: treatment effect inputs and planned scenario analyses
ICER model analysis plan: mortality inputs by Shoulson and Fahn stage
ICER model analysis plan: health state utilities by Shoulson and Fahn stage
| Parameter | Value [95% CI] |
|---|---|
| SF stage 1 | “0.78 [0.72-0.85]” |
| SF stage 2 | “0.66 [0.59-0.73]” |
| SF stage 3 | “0.54 [0.48-0.61]” |
| SF stages 4 and 5 | “0.22 [0.11-0.32]” |
ICER model analysis plan: placeholder price, analyst price estimates, and administration cost
ICER model analysis plan: serious adverse event rates and costs
ICER model analysis plan: annual background health care costs by stage from U.S. Medicaid claims
| Cost category | Early, mean (SD) | Middle, mean (SD) | Late, mean (SD) |
|---|---|---|---|
| All-cause costs | “$28,454 ($39,546)” | “$69,016 ($161,376)” | “$118,889 ($75,136)” |
| All-cause inpatient | “$4,732 ($23,882)” | “$5,311 ($13,850)” | “$85,949 ($55,241)” |
| All-cause outpatient | “$14,509 ($23,438)” | “$45,458 ($160,444)” | “$13,593 ($29,679)” |
| HD-related costs | “$12,444 ($28,673)” | “$28,064 ($45,593)” | “$82,466 ($67,642)” |
| HD-related inpatient | “$769 ($2,962)” | “$2,986 ($7,824)” | “$63,663 ($58,588)” |
| HD-related outpatient | “$5,519 ($17,680)” | “$11,318 ($33,281)” | “$6,055 ($21,301)” |
| HD-related pharmacy | “$6,156 ($22,633)” | “$13,760 ($30,473)” | “$12,748 ($32,671)” |
ICER model analysis plan: annual societal costs by stage
| Cost category | Early | Middle | Late |
|---|---|---|---|
| Direct nonmedical (mean) | “$2,058” | “$2,602” | “$2,294” |
| Indirect (mean) | “$85,656” | “$133,500” | “$112,816” |
ICER model analysis plan: model outcomes and sensitivity analyses
ICER model analysis plan: potential budget impact methods and threshold
ICER model analysis plan: eligible U.S. population and uptake
ICER model analysis plan: exploratory preclinical population
ICER methods for single and short-term therapies: definition, shared savings, and durability threshold
uniQure potential long-term growth levers for the addressable population
uniQure annual report: payer scrutiny of price and cost-effectiveness, and the CMS GENEROUS Model
One-time gene therapy price: Zolgensma list price and installment option at approval
Gene therapy price: Hemgenix list price and the ICER placeholder price and cost-offset cap analysis
Gene therapy price: Roctavian wholesale acquisition cost and outcomes-based warranty
Roctavian market withdrawal
Gene therapy price: Elevidys wholesale acquisition cost
Gene therapy price: eladocagene exuparvovec-tneq wholesale acquisition cost in the USA, stereotactic administration cost, and cost per QALY in a PTC Therapeutics-funded analysis
“For costing of eladocagene exuparvovec-tneq treatment, the list price (wholesale acquisition cost, WAC) in the USA of $3,950,000” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost of administration, $106,030, is a proxy value for the cost of the stereotactic procedure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incremental cost per QALY ranged from $199,007–$224,104.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by PTC Therapeutics Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gene therapy price: Beqvez
Beqvez discontinuation
Payment models for gene therapy: Beqvez warranty program
Payment models for gene therapy: Hemgenix value-based arrangement offered to commercial and government payers
Payment models for gene therapy: value-based contracts, warranties, and short-term budget impact for U.S. payers
“Value-based contracts fall broadly into three categories: milestone-based rebates, warranties and performance-based installment payments (sometimes referred to as an annuity).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, patients treated with gene therapies may change insurers during the term of any payment contract, greatly complicating efforts to track outcomes and link them to additional rebates, a warranty, or performance-based installment payments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A third barrier, Medicaid Best Price (MBP) provisions, applies to all value-based contracts except warranties” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, Roctavian™ launched with an outcomes-based warranty offered to all US insurers, which will reimburse payers on a pro-rated basis over the first 4 years from the time of dosing if the patient loses response – up to 100% of wholesale acquisition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For these payers, an unpredictable $1–3 million treatment may be such a large percentage of their annual health costs that an upfront payment would be financially destabilizing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All told, 85 new gene therapies across more than 12 therapeutic areas are expected to receive regulatory approval by 2032, with an estimated ten-year list price spend of $35 to $40 billion” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Payment models for gene therapy: CMS Cell and Gene Therapy Access Model
Budget impact of etranacogene dezaparvovec in a hypothetical 1-million-member health plan, funded by CSL Behring
“The model considered a hypothetical 1-million-member plan over a 5-year horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 1-million-member health plan, an estimated 1.8 PwHB were eligible for treatment with etranacogene dezaparvovec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gradual uptake of etranacogene dezaparvovec resulted in cumulative 5-year budget impact of $848,509 compared with a scenario without etranacogene dezaparvovec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In years 1-5, the incremental annual and per-member per-month costs ranged from $79,824 to $271,435 and from $0.007 to $0.023, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Etranacogene dezaparvovec price was assumed to be $3,500,000 as a single administration (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the analysis assuming 100% uptake of etranacogene dezaparvovec in year 1, incremental annual cost of $4.843 million (Figure 2A) or $0.40 PMPM” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Scenario analyses (Table 3) showed that the 5-year budget impact results were sensitive only to the assumptions regarding uptake of etranacogene dezaparvovec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was conducted by RTI Health Solutions and funded by CSL Behring LLC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. cost-effectiveness analysis of tominersen and AMT-130 in early-stage HD
“A Markov model with four health states (early, middle, late, and death) was developed to estimate lifetime costs and benefits from a modified societal perspective, with death as an absorbing state.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As per the incremental cost-effectiveness ratio (ICER) value assessment framework, a willingness-to-pay threshold (WTP) of $500,000/QALY gained was considered given that HD is a rare disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with SoC, Tominersen increased costs by $2.11 million and QALYs by 0.93, resulting in an ICER of $2.28 million per QALY gained, whereas AMT-130 increased costs by $1.49 million and QALYs by 5.23, resulting in an ICER of $285,703 per QALY gained in the base case.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic analysis showed AMT-130 had 80% probability of being cost-effective at $350,000/QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further evidence on long-term effectiveness and durability is needed to inform policy and reimbursement decisions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. cost-effectiveness analysis of tominersen and AMT-130: model structure, perspective, and time horizon
“A modified societal perspective was adopted to capture direct healthcare costs and non-healthcare costs such as caregiver burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cycle length was 1 year with an annual discount rate of 3% used for all future costs and utilities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a total of 30 annual cycles were considered sufficient to capture lifetime costs and health outcomes associated with the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients entered the model in the early stage, and at the end of each cycle, they could transition into a different health stage, stay in the early stage, or experience death” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For Tominersen, we postulated that even though the drug would result in slowing the disease progression, it would not result in disease reversal. Therefore, we made an assumption on the basis of expert opinion that the probability of disease progression from the early stage to the middle stage would reduce from 0.16 to 0.1 for the base-case model” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Utilities for Tominersen and AMT-130 were assumed equal to SoC because trial-based utility data are not yet available.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. cost-effectiveness analysis: standard of care inputs by disease stage
U.S. cost-effectiveness analysis: drug price and administration cost assumptions
“Since Tominersen and AMT-130 are currently in clinical trials, we lacked established cost data and therefore relied on cost estimates from treatments for spinal muscular atrophy (SMA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After accounting for the discount, the estimated cost of a single 60 mg injection of Tominersen was $106,250.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on this schedule, the estimated annual cost of Tominersen was $318,750.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Considering these similarities, the cost for AMT-130 was assumed to be the same as the list price for Zolgensma” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The regular payer discount of 15% was then applied to the list price, for a one-time dose of AMT-130, which was estimated to be $1,806,250.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment arm administration cost | Base case |
|---|---|
| Tominersen | “$3627”View highlighted excerpt for this quote |
| AMT-130 | “$23,516”View highlighted excerpt for this quote |
U.S. cost-effectiveness analysis: base-case results
U.S. cost-effectiveness analysis: scenario and sensitivity analyses
“After considering the additional value of hope to the base-case utility value, the total QALYs for Tominersen increased from 7.03 to 7.49, and for AMT-130, it increased from 11.34 to 12.43.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, the ICER value decreased significantly from $2.28 million per QALY gained to $1.52 million per QALY gained for Tominersen, and for AMT-130, it changed from $285,703 per QALY gained to $236,540 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One-way sensitivity analyses indicated that the ICERs were most sensitive to the cost of the drugs, particularly AMT-130 and Tominersen, as well as health-state utility values for early and middle-stage HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost-effectiveness acceptability curve revealed that the probability of AMT-130 being considered cost-effective at a WTP threshold of $250,000 per QALY gained was 30%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The probability of Tominersen being considered cost-effective was 0% throughout the curve” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings from the PSA also indicated that the probability of both of the treatments being considered cost-effective was 0% at the conventional WTP threshold of $100,000–150,000 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. cost-effectiveness analysis: stated limitations
“The model relied on many assumptions and simplifications owing to limited clinical trial evidence and the lack of established cost data for Tominersen and AMT-130.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model relied heavily on the assumption of sustained benefit for both treatments beyond the data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The statistical generalizability or the comparative efficacy of AMT-130 and Tominersen with the SoC cannot be assessed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, it should be noted that the Tominersen trial recently updated its protocol to continue only the 100-mg dose” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. decision-modeling framework for future disease-modifying treatments
“The lifetime costs of HD were $508,200 ($310,300 to $803,700) for the PFD population, $1.15 million ($684,500 to $1.89 million) for SF1 individuals, and $1.07 million ($571,700 to $2.26 million) for SF2 individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recent research estimates that annual costs associated with HD in the United States ranges from $6,600 to $30,300 per year depending on the stage of progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the DMTs currently under development vary in mechanism of action (small molecule, ASO, gene therapy), route of administration (oral, intrathecal, intraparenchymal), and once vs recurrent therapy; these contingencies make it difficult at this time to assign a DMT price in our exploratory analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom progression model with societal cost estimation
“Data from the Enroll-HD observational study were used to fit a continuous-time hidden Markov disease progression model, which identified five distinct states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the results of the UK cost modelling show that indirect costs of HD such as state benefits and lost gross domestic product contribution could be the driving factors for the societal cost, over and above health and social care costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health technology assessment: ICER assessment of AMT-130 announced
Health technology assessment: ICER draft scope for population, comparator, and planned models
United States all-state closed claims: annual prevalence of diagnosed Huntington's disease per 100,000, 2020 to 2024
| Year | Prevalence rate per 100,000 (95% CI) |
|---|---|
| 2020 | “6.7 (6.3-7.1)” |
| 2021 | “7.4 (7.0-7.8)” |
| 2022 | “7.9 (7.5-8.3)” |
| 2023 | “8.4 (8.0-8.8)” |
| 2024 | “9.4 (8.9-9.8)” |
British Columbia: multisource prevalence of Huntington's disease
“Prevalence of HD was estimated at 13.7 per 100,000 (95% confidence interval [CI]: 12.6-14.8 per 100,000) in the general population, and 17.2 per 100,000 (95% CI: 15.8-18.6 per 100,000) in the Caucasian population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States commercial claims: share of diagnosed people aged 20 years or younger
North American Enroll-HD participants with manifest Huntington's disease: Total Functional Capacity stage
“Most participants were in TFC stages I–III, with the highest proportion (41.3%) of participants in stage II (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Stage (Total Functional Capacity score) | Participants |
|---|---|
| Stage I (11 to 13) | “n = 845”View highlighted excerpt for this quote |
| Stage II (7 to 10) | “n = 1068”View highlighted excerpt for this quote |
| Stage III (3 to 6) | “n = 540”View highlighted excerpt for this quote |
| Stage IV (1 to 2) | “n = 116”View highlighted excerpt for this quote |
| Stage V (0) | “n = 15”View highlighted excerpt for this quote |